Druggable molecular targets for the treatment of triple negative breast cancer
| Title: | Druggable molecular targets for the treatment of triple negative breast cancer |
|---|---|
| Authors: | M Nakhjavani; JE Hardingham; HM Palethorpe; TJ Price; AR Townsend |
| Publication Year: | 2019 |
| Subject Terms: | Science & Technology; Life Sciences & Biomedicine; Oncology; Clinical trial; Drug therapy; Triple negative breast neoplasms; RANDOMIZED PHASE-II; CONJUGATE GLEMBATUMUMAB VEDOTIN; BEVACIZUMAB-CONTAINING THERAPY; TRANSFORMING-GROWTH-FACTOR; FACTOR RECEPTOR; MESSENGER-RNA; BRCA MUTATION; CHEMOTHERAPY; TRIAL; INHIBITION; 3211 Oncology and carcinogenesis; 3214 Pharmacology and pharmaceutical sciences |
| Description: | Druggable molecular targets for the treatment of triple negative breast cancer |
| Document Type: | article in journal/newspaper |
| Language: | unknown |
| Relation: | http://hdl.handle.net/10536/DRO/DU:30159015; https://figshare.com/articles/journal_contribution/Druggable_molecular_targets_for_the_treatment_of_triple_negative_breast_cancer/20634960 |
| Availability: | http://hdl.handle.net/10536/DRO/DU:30159015; https://figshare.com/articles/journal_contribution/Druggable_molecular_targets_for_the_treatment_of_triple_negative_breast_cancer/20634960 |
| Rights: | CC BY-NC 4.0 |
| Accession Number: | edsbas.C8E2A6E2 |
| Database: | BASE |